Browse Category

NYSE:YOU News 14 December 2025

Clear Secure (YOU) Stock News on Dec. 14, 2025: CMS Medicare.gov Deal, JPMorgan Upgrade, Insider-Sale Filing, and Updated Price Targets

Clear Secure (YOU) Stock News on Dec. 14, 2025: CMS Medicare.gov Deal, JPMorgan Upgrade, Insider-Sale Filing, and Updated Price Targets

As of Sunday, December 14, 2025, Clear Secure, Inc. (NYSE: YOU) is one of the most talked-about mid-cap “digital identity” names after a sharp rally that pushed the stock to fresh multi-year highs in the last trading session. The move has been fueled by a major U.S. government-related healthcare contract, a bullish JPMorgan analyst upgrade, and renewed debate about whether Clear is transitioning from a travel-adjacent membership business into a broader, reusable identity platform for highly regulated industries. Clear Secure, Inc. Below is a complete, publication-ready rundown of the latest Clear Secure stock news, forecasts, and analyses available as of
14 December 2025

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Go toTop